Daito Pharmaceutical (4577) · RiskMitigated
Customer Credit Risk
First written in FY2017. 10 of 24 entries say "Worsened", first in FY2021-Q1. Latest entry: FY2026.
24entries
10years
1from disclosures
How it moved
Same theme, other companies
Credit Risk Management for Business PartnersA theme 903 companies write about · 923 as a headwind · 18 as a tailwind
The whole theme swung hardest in 2026: 19 of 65 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 194 companies compared. The sentences above are computed from all 194.Comparing 200 of the theme's 942 threads.Full recordFilings, disclosures and news, newest first
- FY2026MitigatedAnnual report
「Total 52」
Total guarantees of liabilities for accounts payable decreased from ¥156 million at the end of the previous fiscal year to ¥52 million, reducing guarantee exposure related to customer credit. - 2026-07-30MitigatedGeneral Meetings of Shareholders
「Total ¥52 million」
Guarantees of trade payables to Takeda Pharmaceutical Company Limited totaled ¥52 million, down from ¥58 million disclosed immediately before for FY2026-H1. - FY2026-H1MitigatedAnnual report
「Total 58」
Total guarantees of liabilities for accounts payable decreased from ¥156 million at the end of the previous fiscal year to ¥58 million, reducing guarantee exposure related to customer credit. - FY2025MitigatedAnnual report
「Total 156」
Total guarantees of liabilities for accounts payable to Takeda Pharmaceutical Company Limited decreased from ¥191 million at the end of the previous fiscal year to ¥156 million, reducing guarantee exposure related to customer credit. - FY2025-H1MitigatedAnnual report
「勝山ファーマ㈱ ¥82 million ㈱富士薬品 29 第一薬品工業㈱ 2 ㈱パナケイア製薬 1 富山めぐみ製薬㈱ 1 Total 117」
Total guarantees of liabilities for accounts payable decreased from ¥191 million at the end of the previous fiscal year to ¥117 million, reducing guarantee exposure related to customer credit. - FY2024WorsenedAnnual report
「Total 191」
Total guarantees and other obligations for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥98 million at the end of the previous fiscal year to ¥191 million, increasing guarantee exposure related to customer credit. - FY2024-Q3WorsenedAnnual report
「Total 336」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥98 million at the end of the previous consolidated fiscal year to ¥336 million, increasing guarantee exposure related to customer credit. - FY2024-Q2WorsenedAnnual report
「Total 129」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥98 million at the end of the previous consolidated fiscal year to ¥129 million, increasing guarantee exposure related to customer credit. - FY2024-Q1WorsenedAnnual report
「Total 121」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥98 million at the end of the previous consolidated fiscal year to ¥121 million, increasing guarantee exposure related to customer credit. - FY2023WorsenedAnnual report
「Total 98」
Total guarantees and other obligations for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥15 million at the end of the previous fiscal year to ¥98 million, increasing guarantee exposure related to customer credit. - FY2023-Q3WorsenedAnnual report
「Total 142」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥15 million at the end of the previous consolidated fiscal year to ¥142 million, increasing guarantee exposure related to customer credit. - FY2023-Q1WorsenedAnnual report
「Total 50」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥15 million at the end of the previous consolidated fiscal year to ¥50 million, increasing guarantee exposure related to customer credit. - FY2022MitigatedAnnual report
「Fuji Yakuhin Co., Ltd. ¥15 million Total 15」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited decreased from ¥22 million at the end of the previous fiscal year to ¥15 million, reducing guarantee exposure related to customer credit. - FY2022-Q3WorsenedAnnual report
「Total 67,188」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥22.059 million at the end of the previous consolidated fiscal year to ¥67.188 million, increasing guarantee exposure. - FY2022-Q2MitigatedAnnual report
「Total 34,343」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited were ¥34.343 million, with guarantee exposure decreasing from the ¥48.497 million reported immediately before, in FY2022-Q1. - FY2022-Q1MitigatedAnnual report
「Total 48,497」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited were ¥48.497 million. Guarantee exposure decreased from the ¥112.853 million reported immediately before, in FY2021-Q3. - FY2021-Q3WorsenedAnnual report
「Total 112,853」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥86.022 million at the end of the previous consolidated fiscal year to ¥112.853 million, increasing guarantee exposure. - FY2021-Q2MitigatedAnnual report
「Total 72,160」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited decreased from ¥86.022 million at the end of the previous consolidated fiscal year to ¥72.160 million. Guarantee exposure related to customer credit has decreased. - FY2021-Q1WorsenedAnnual report
「Total 235,308」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥86.022 million at the end of the previous consolidated fiscal year to ¥235.308 million. Guarantee exposure related to customer credit has increased. - FY2020-Q3Increase in outstanding guaranteesAnnual report
「Total 216,371」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥72.614 million at the end of the previous consolidated fiscal year to ¥216.371 million. - FY2020-Q2Increase in outstanding guarantees from the end of the previous fiscal yearAnnual report
「Total 108,014」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥72.614 million at the end of the previous consolidated fiscal year to ¥108.014 million. - FY2020-Q1Increase in outstanding guaranteesAnnual report
「Total 213,533」
Total guarantees for accounts payable to Takeda Pharmaceutical Company Limited increased from ¥72.614 million at the end of the previous consolidated fiscal year to ¥213.533 million. - FY2018RestatedAnnual report
「Notes and accounts receivable, electronic receivables and factoring receivables, all of which are trade receivables, are exposed to customers' credit risk. The company has a system in place to monitor customers' credit standing in relation to this risk.」
It reiterates customers' credit risk on trade receivables and the management system for monitoring their credit standing. - FY2017First statedAnnual report
「Notes and accounts receivable, electronic receivables and factoring receivables, all of which are trade receivables, are exposed to customers' credit risk. The company has a system in place to monitor customers' credit standing in relation to this risk.」
The notes to financial instruments explicitly describe customers' credit risk on trade receivables and the management system for monitoring their credit standing.